Will CVS Earnings Miss this Quarter? - Analyst Blog
30 4월 2013 - 11:40PM
Zacks
CVS Caremark (CVS) is scheduled to report its first-quarter 2013
results before the opening bell on May 1. In the last quarter, CVS
Caremark reported a 2.73% positive earnings surprise on the heels
of robust growth across both operating platforms. Let us see how
things are shaping up for this integrated pharmacy services
provider prior to the announcement.
Factors to Consider this Past Quarter
CVS Caremark’s bright prospects for 2013 on the heels of solid
earnings forecast, stronger balance sheet, favorable selling season
and positive industry dynamics are encouraging. On the domestic
front, demographic trends, healthcare reforms in the U.S., and the
generic wave in the pharmaceutical industry are expected to
catalyze growth for the company. In light of these trends, CVS
Caremark expects accelerating adoption of its programs such as
Maintenance Choice, Pharmacy Advisor and ExtraCare loyalty program,
along with expansion of its MinuteClinics.
As per management, the company continues to win market share in
retail pharmacy. In the meantime, the tussle with Walgreens (WAG)
to gain market share has intensified. Macroeconomic uncertainty is
another looming concern.
Earnings Whispers?
Our proven model does not conclusively show that CVS Caremark is
likely to beat earnings estimate this quarter. That is because a
stock needs to have both a positive Earnings ESP (Read: Zacks
Earnings ESP: A Better Method) and a Zacks Rank of #1, 2 or 3 for
this to happen. This is not the case here, as you will see
below.
Zacks Earnings ESP: The Most Accurate estimate stands at 78 cents,
while the Zacks Consensus Estimate is pegged at 79 cents. This
comes to a difference of -1.27%.
Zacks Rank #2 (Buy): CVS Caremark’s Zacks Rank #2 diffuses the
predictive power of ESP. The Zacks Rank #2 together with -1.27%
earnings ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some other companies from the healthcare sector you may
want to consider as our model shows they have the right ingredients
to post an earnings beat this quarter:
Coventry Health Care Inc. (CVH), Earnings ESP of +5.06% and
Zacks Rank #2 (Buy)
Henry Schein (HSIC), Earnings ESP of +3.74% and Zacks Rank #3
(Hold)CVS Caremark (CVS) is scheduled to report its first-quarter
2013 results before the opening bell on May 1. In the last quarter,
CVS Caremark reported a 2.73% positive earnings surprise on the
heels of robust growth across both operating platforms. Let us see
how things are shaping up for this integrated pharmacy services
provider prior to the announcement.
CVS Caremark
(CVS) is scheduled to report its first-quarter 2013 results before
the opening bell on May 1. In the last quarter, CVS Caremark
reported a 2.73% positive earnings surprise on the heels of robust
growth across both operating platforms. Let us see how things are
shaping up for this integrated pharmacy services provider prior to
the announcement.
Factors to Consider this
Past Quarter
CVS Caremark’s bright prospects
for 2013 on the heels of solid earnings forecast, stronger balance
sheet, favorable selling season and positive industry dynamics are
encouraging. On the domestic front, demographic trends, healthcare
reforms in the U.S., and the generic wave in the pharmaceutical
industry are expected to catalyze growth for the company. In light
of these trends, CVS Caremark expects accelerating adoption of its
programs such as Maintenance Choice, Pharmacy Advisor and ExtraCare
loyalty program, along with expansion of its
MinuteClinics.
As per management, the company
continues to win market share in retail pharmacy. In the meantime,
the tussle with Walgreens (WAG) to gain market
share has intensified. Macroeconomic uncertainty is another looming
concern.
Earnings
Whispers?
Our proven model does not
conclusively show that CVS Caremark is likely to beat earnings
estimate this quarter. That is because a stock needs to have both a
positive Earnings ESP (Read: Zacks Earnings ESP: A Better
Method) and a Zacks Rank of #1, 2 or 3 for this to happen.
This is not the case here, as you will see below.
Zacks Earnings ESP: The Most
Accurate estimate stands at 78 cents, while the Zacks Consensus
Estimate is pegged at 79 cents. This comes to a difference of
-1.27%.
Zacks Rank #2 (Buy): CVS
Caremark’s Zacks Rank #2 diffuses the predictive power of ESP. The
Zacks Rank #2 together with -1.27% earnings ESP makes surprise
prediction difficult.
Other Stocks to
Consider
Here are some other companies
from the healthcare sector you may want to consider as our model
shows they have the right ingredients to post an earnings beat this
quarter:
Coventry Health Care
Inc. (CVH), Earnings ESP of +5.06% and Zacks Rank #2
(Buy)
Henry Schein
(HSIC), Earnings ESP of +3.74% and Zacks Rank #3 (Hold)
COVENTRY HLTHCR (CVH): Free Stock Analysis Report
CVS CAREMARK CP (CVS): Free Stock Analysis Report
HENRY SCHEIN IN (HSIC): Free Stock Analysis Report
WALGREEN CO (WAG): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Coventry Hlth Care (NYSE:CVH)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Coventry Hlth Care (NYSE:CVH)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024